duplication mutations in 956 adult patients with acute myeloid leukemia. *Genes Chromosomes Cancer* 2003; **37**: 237–251.

9 Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo myeloid leukemia. *N Engl J Med* 2013; **368**: 2059–2074.

10 Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J *et al*. Recurrent mutations in the *U2AF1* splicing factor in myelodysplastic syndromes. *Nat Genet* 2011; **44**: 53–57.

11 Abu Kar S, Jankowska A, Makishima H, Visconte V, Jerez A, Sugimoto Y *et al*. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. *Haematologica* 2013; **98**: 107–113.

12 Herold T, Metzeler KH, Vosberg S, Hartmann L, R�llig C, St�lzel F *et al*. Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of

mutations in spliceosome genes and poor prognosis. *Blood* 2014; **124**: 1304–1311.

13 Caligiuri MA, Strout MP, Oberkircher AR, Yu F, de la Chapelle A, Bloomfield CD. The partial tandem duplication of *ALL1* in acute myeloid leukemia with normal cytogenetics or trisomy 11 is restricted to one chromosome. *Proc Natl Acad Sci USA* 1997; **94**: 3899–3902.

14 Whitman SP, Liu S, Vukosavljevic T, Rush LJ, Yu L, Liu C *et al*. The *MLL* partial tandem duplication: evidence for recessive gain of function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. *Blood* 2005; **106**: 345–352.

15 Kao H-W, Liang D-C, Kuo M-C, Wu J-H, Dunn P, Wang P-N *et al*. High frequency of additional gene mutations in acute myeloid leukemia with *MLL* partial tandem duplication: *DNMT3A* mutation is associated with poor prognosis. *Oncotarget* 2015; **6**: 33217–33225.

Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)

OPEN

Standardization of molecular monitoring for chronic myeloid leukemia in Latin America using locally produced secondary cellular calibrators

Residual disease in chronic myeloid leukemia (CML) patients undergoing therapy with tyrosine kinase inhibitors (TKIs) is measured by assessing the quantity of transcripts of the *BCR-ABL1* fusion gene in peripheral white blood cells.[1] This analysis is based on reverse-transcription quantitative PCR (RT–qPCR) technology; however, the wide array of methods used worldwide has led to large variation in quantitative *BCR-ABL1* measurements, which hamper inter-laboratory comparative studies.[2,3] It is now recognized that monitoring *BCR-ABL1*/control gene ratios on the International Scale (IS) is vital for the management of patients with CML.[4] Efforts to harmonize procedures to measure *BCR-ABL1* fusion transcripts have included important investments in sample exchange programs to derive laboratory-specific conversion factors (CF); these efforts showed improvements in inter-laboratory concordance rates, but the process is laborious and limited due to the lack of a common set of reference samples that can be shared on a global scale. This requirement was recently addressed in part by the formulation and validation of the first World Health Organization (WHO) International Genetic Reference Panel for quantitation of *BCR-ABL1* by RT–qPCR.[5] The WHO primary standards consist of a four-level panel of e14a2-positive lyophilized cell line dilutions. Each level has an assigned IS value, which was obtained by repeated testing of each sample level in expert IS-standardized laboratories. Unfortunately, the stock of WHO primary standards is limited, and their accessibility has been restricted to manufacturers of testing kits or secondary reference standards. In this study, we aimed to develop and validate secondary reference materials calibrated to the IS through the WHO primary standards in order to facilitate standardization of molecular monitoring in Latin America.

The study design comprised five principal steps as illustrated in Supplementary Figure 1. The study was conducted by a single reference laboratory (rLAB, Buenos Aires, Argentina), which initially obtained a CF to the IS by sample exchange with the reference laboratory in Adelaide in 2010. To ensure consistent performance of the rLAB analytical system (MolecularMD, Portland, OR, USA), we included two quality control RNA samples with a high and low *BCR-ABL1* level in each run (Supplementary Table 1 and Supplementary Material and Method, Section 1). To further validate our method prior to calibration of secondary reference materials (see below), we derived a CF by using WHO primary standards (NIBSC code 09/138) from the United Kingdom National Institute for Biological Standards and Control (Potters Bar, Hertfordshire, UK). The antilog of the estimated mean bias (−0.152) was designated as the conversion factor (CF = 0.7) for the rLAB method (Supplementary Table 2), which is very close (that is, well within twofold) to the value of 0.45 obtained by sample exchange 3 years previously.

Previous local exploratory investigation indicated that RT–qPCR methodology harmonization was necessary since the tests were inadequately comparable, considering that the three acceptance criteria proposed by Muller *et al*.[6] were not satisfied (Supplementary Tables 3 and 4). To this aim, we established and validated five batches of cellular calibrators produced by serial dilution of the Ph-positive cell line K562 in the Ph-negative cell line HL-60. Formulations were planned to target IS% ratios close to each of the established TKI clinical response criteria,[7–9] that is, between 10%, 1%, 0.1% ($MR^{3.0}$) and 0.01% ($MR^{4.0}$). An additional dilution (0.001%, $MR^{5.0}$) was included in order to assess the limit of detection of the methods and was not considered for the estimation of the CF (Figure 1). Cell mixes were stabilized by lyophilization (Supplementary Figure S2A); assignment of IS% values to each batch and level of these secondary standards was achieved by repeated testing of randomly picked ampoules on 4 non-consecutive days (Figure 1 and Supplementary Material and Method, Section 2). Stability studies of the freeze-dried cells showed no significant changes in the *BCR-ABL1/ABL1* ratio over time at different temperatures up to 6 months (Supplementary Figure 2B). The calibrated secondary reference standards were

Figure 1. Study design for the nominal IS% value assignment and *BCR-ABL1* testing by participating laboratories.


Figure 2. (**a**) Relative difference between nominal and measured IS% ratios for all calibrator levels combined (black circle). (**b**) Residual difference after CF conversion. Error bars show 95% LOA interval. (**c**) Correlation graph. Comparison of IS% ratios from 41 whole blood samples, interchanged between the rLAB and local Lab#09. Gray-colored squares represent the concordance area for the assignment of the molecular response. Black points, concordant results. Red points, discordant results. Black line, equality line.

distributed to 18 testing laboratories from seven countries in Latin America. Each laboratory followed the calibrators' instructions for use, which recommended four independent runs on different days for the two panels (Supplementary Materials and Methods, Section 3). A total of 1312 RT–qPCR positive results were generated; mean raw percentage ratios generated in all laboratories were consistent with a 10-fold serial dilution and were linear for the first four levels (Supplementary Figure S3); before CF calculation, in order to assess if bias was uniform across the *BCR-ABL1* expression range, Bland–Altman analysis[10] was performed for each assay (Supplementary Material and Method, Section 4). All the assays showed a uniform bias, indicating that a valid CF could be calculated for these methods (Supplementary Table 5). All raw percentage ratios measured within the linear range of each local RT–qPCR method were compared against a single set of reference values, the nominal IS% ratios. Laboratory-specific CFs

were calculated by Bland–Altman method[10] (Supplementary Table 5). The relative mean bias ranged from − 0.45-fold to +0.25-fold in distinct laboratories (Figure 2a); after correction of the individual raw percent ratios with the laboratory-specific CF, the residual mean bias was null (Figure 2b, Supplementary Figure S4). In addition, raw *BCR-ABL1/ABL1* percent ratios generated in each laboratory were used to assess the corresponding level-specific coefficient of variation (CV): between 8 and 58% (12 out of 18 laboratories with an average CV less than 30%). As expected, *BCR-ABL1* was inconsistently detected below the linear quantitative detection range of the RT–qPCR method in the lowest positive samples (fifth calibrator); for the 10 laboratories that tested the fifth calibrator, the overall *BCR-ABL1* detection rate ranged from 12.5 to 100%. In total, eight out of ten laboratories could reproducibly detect *BCR-ABL1* in level-5 samples (Supplementary Table 5). Interestingly, five laboratories had previous standardization;

thus we could compare the new CF with the laboratory's current CF; when no methodology modifications were introduced since the time of the last calibration, we obtained highly concordant CFs (Supplementary Table 6).

For appropriate clinical decisions, we need to judge agreement between the methods after IS conversion; to this aim, we interchanged 41 whole blood samples (divided into two parts) from CML patients with Lab#09. The concordance in MR[IS] between the reference method and the external laboratory was 88% after conversion (36 out of 41 samples were in the same MR category) (Figure 2c). This result underlines the importance of conversion to the IS, given that after harmonization we were able to halve the number of discordant data (from nine to five cases).

In the present study, we show that secondary reference biological calibrators anchored to the WHO primary standards can decrease inter-laboratory variability. Our results, together with those recently reported by Cross et al.,[11] substantiate the objective initially set during the establishment of the WHO primary standards, that is, to facilitate worldwide diffusion of the IS. For the first time in Latin America, this study provides a platform on which to assess the performance of distinct clinical *BCR-ABL1* tests and confirm the utility of secondary reference materials to further improve IS accuracy and inter-laboratory precision. This effort will continue in the future by providing secondary reference material to the centers involved in this project and potential new participants; moreover, due to its higher precision and absolute quantification capability, we are evaluating the possibility of including digital PCR as the calibration method for the future.

MS Ruiz[1], M Medina[2], I Tapia[1], J Mordoh[1], NCP Cross[3,4], I Larripa[2] and M Bianchini[1]
[1]Centro de Investigaciones Oncológicas–Fundación Cáncer (CIO-FUCA), Instituto Alexander Fleming, Buenos Aires, Argentina;
[2]Instituto de Medicina Experimental (IMEX), CONICET-Academia Nacional de Medicina, Buenos Aires, Argentina;
[3]Faculty of Medicine, University of Southampton, Southampton, UK and
[4]National Genetics Reference Laboratory (Wessex), Salisbury, UK
E-mail: mbianchini@conicet.gov.ar

REFERENCES

1 Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia Net. J Clin Oncol 2009; 27: 6041–6051.
2 Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006; 20: 1925–1930.
3 Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European leukemia net recommendations for the management of chronic myeloid leukemia. Blood 2013; 122: 872–884.
4 Branford S, Fletcher L, Cross NC, Müller MC, Hochhaus A, Kim DW et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112: 3330–3338.
5 White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Lynn Wang Y et al. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood 2010; 116: e111–e117.
6 Müller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009; 23: 1957–1963.
7 Cross NC, White HE, Müller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26: 2172–2175.
8 Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 2015; 29: 999–1003.
9 Morley AA. Reporting results for deep molecular responses in chronic myeloid leukemia. Leukemia 2016; 30: 1630–1631.
10 Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307–310.
11 Cross NC, White HE, Ernst T, Welden L, Dietz C, Saglio G et al. Development and evaluation of a secondary reference panel for BCR-ABL1 quantitation on the International Scale. Leukemia 2016; 30: 1844–1852.

Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)

HLA polymorphism and risk of multiple myeloma

The two- to threefold increased risk of multiple myeloma (MM) within families, and among African Americans vs Whites support a role of genetic factors in disease development.[1,2] Human leukocyte antigen (HLA) proteins initiate immune surveillance through peptide presentation to T-cell receptors.[3] Each HLA allele has the capability of presenting a differing limited repertoire of peptides derived from self and non-self proteins, therefore HLA polymorphim has been associated with numerous immune-mediated diseases.[4]

A genome-wide association study (GWAS) of MM identified a risk variant within the major histocompatibility complex